EBR Systems Completes interim enrolment for SOLVE trial
- EBR Systems (EBR) completes interim patient enrolment in the pivotal SOLVE-CRT IDE trial of WiSE
- The trial is evaluating the safety and efficacy of the WiSE System in up to 300 patients with acute lead failures, chronic lead failures, high-risk upgrades and leadless upgrades
- WiSE is a wireless, endocardial pacing system for use in stimulating the heart’s left ventricle which is believed to be the more anatomically correct location for pacing equipment
- EBR has also executed a five-year agreement for a US$50 million (A$72.63 million) growth capital facility with venture debt provider, Runway Growth Capital
- Shares in EBR are up 41 per cent and were trading at 53 cents at 1:12 pm
